

Special Issue

From Pathophysiology to Novel Therapeutic Approaches in Alzheimer's Disease

Message from the Guest Editor

Alzheimer's disease (AD) is a very complex disease affecting millions of people worldwide and representing the first cause of cognitive deterioration and dementia. Despite the advances in research and therapeutics, the prevalence of this condition is increasing, and treatments are still poorly effective in preventing but also avoiding disease progression. Several pathophysiological mechanisms have been suggested in recent years, and novel therapeutic approaches, such as specific anti-Ab monoclonal antibodies, have been introduced in clinical practice. With this Special Issue of *Biomedicines*, we aim to provide novel insights into the AD pathophysiology of Alzheimer's disease, exploring the underlying mechanisms and processes involved in the development and progression of the condition. We also aim to discuss current and emerging treatment strategies, including pharmacological and non-pharmacological interventions. We will consider original research articles as well as systematic and narrative reviews on the topics covered by this Special Issue. Thank you for considering this invitation, and I look forward to your valuable contributions to this collaborative effort.

Guest Editor

Dr. Lorenzo Falsetti

Department of Emergency Medicine, Internal and Sub-Intensive Medicine, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", 60166 Ancona, Italy

Deadline for manuscript submissions

closed (31 May 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/222912

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).